Work

Towards new business models for R&D for novel antibiotics

Year: 2011

Type: review

Source: Drug Resistance Updates

DOI: 10.1016/j.drup.2011.01.006

Authors: A.D. So, N. Gupta, S.K. Brahmachari, I. Chopra, B. Munos, C. Nathan, K. Outterson, J.P. Paccaud, D.J. Payne, R.W. Peeling, M. Spigelman, J. Weigelt

Institutions: Duke University, Open Source Drug Discovery, Council of Scientific and Industrial Research, University of Leeds, Weill Cornell Medicine, Boston University, Drugs for Neglected Diseases Initiative, GlaxoSmithKline (United States), London School of Hygiene & Tropical Medicine, TB Alliance, Karolinska Institutet

Language: English

Topic: Pharmaceutical Economics and Policy

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDGs: Good health and well-being, Partnerships for the goals, Industry, innovation and infrastructure

Open Access status: closed

Funder: GlaxoSmithKline

OpenAlex ID: W1987601923

FWCI: 2.746

Cites: 23

Cited by: 80

Related to: 10